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Abstract 
Objective: To develop a core outcome set for the evaluation of interventions that aim to improve how people make decisions about 
whether to participate in randomized controlled trials (of healthcare interventions), the ELICIT Study. 
Study Design: International mixed-method study involving a systematic review of existing outcomes, semi-structured interviews, an 
online Delphi survey, and a face-to-face consensus meeting. 
Results: The literature review and stakeholder interviews (n = 25) initially identified 1045 reported outcomes that were grouped into 
40 individually distinct outcomes. These 40 outcomes were scored for importance in two rounds of an online Delphi survey (n = 79), 
with 18 people attending the consensus meeting. Consensus was reached on 12 core outcomes: therapeutic misconception; comfort with 
decision; authenticity of decision; communication about the trial; empowerment; sense of altruism; equipoise; knowledge; salience of 
questions; understanding, how helpful the process was for decision making; and trial attrition. 
Conclusion: The ELICIT core outcome set is the first internationally agreed minimum set of outcomes deemed essential to be 
measured in all future studies evaluating interventions to improve decisions about participating in an randomized controlled trial. Use 
of the ELICIT core set will ensure that results from these trials are comparable and relevant to all stakeholders. 
Registration: COMET database - http://www.comet-initiative.org/Studies/Details/595. © 2021 The Authors. Published by Elsevier 
Inc. 
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 

























Informed consent is central to participation in clinical
research. The requirement of informed consent for partic-
ipation in randomized controlled trials (RCTs) was estab-
lished to allow people to recognize and consider potential
risks or benefits of participating, and to respect their au-
tonomous choices [1] . The adequacy of these processes
has, however, been called into question [2 , 3] . Concern
stems from evidence that trial participants often lack under-
standing (so cannot be considered "informed”) about the
trial rationale and the risks of interventions [4] . Questions
have also been raised about the absence, from informed
consent processes, of features of “good” decision-making,Conflict of Interest: None. 
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( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) including attention to the influence of context on prefer-
ences, ability to predict future well-being, and integration
of information with personal values and goals [5] . 
Suggestions for improving consent processes have in-
cluded interventions targeting aspects of information pro-
vision, usually the content (including length of infor-
mation, readability, etc) or mode of delivery (e.g., pa-
per, multimedia) [6-8] . Systematic reviews of interventions
to improve participants’ understanding in informed con-
sent for research are inconclusive about their effectiveness
[6-8] . The range of interventions is one reason for this,
but outcome assessment heterogeneity has also hampered
evaluation. 
A raft of outcomes has been proposed in evaluations
of interventions to improve the invitation and recruitment
process in RCTs (now referred to, for short, as the RCT
decision process) [6-9] . Some have focused on how well-
informed potential participants are, or whether they areess article under the CC BY-NC-ND license 

































































































recruited into the trial. However, very few studies have
considered what outcomes are important to potential par-
ticipants or attempted to assess their experiences of the
process. The lack of consistency in outcome measurement
and reporting hampers synthesis across the studies, reduc-
ing the value of this research literature. 
One way to help prioritize and standardize the selection
and reporting of outcomes is to develop a core outcome
set (COS) - a minimum set of outcomes that should be
considered essential to be measured in all evaluations and
reporting of specific interventions or conditions to improve
the informed consent process [10] . 
The ELICIT study aimed to develop such a COS for the
evaluation of interventions that aim to improve how peo-
ple make decisions about whether to participate in RCTs
of healthcare interventions (i.e., those which are delivered
to individuals in healthcare settings and/or by health pro-
fessionals). 
2. Methods 
2.1. Study overview 
The development of the COS followed best practice and
involved three sequential stages [11] . The methods for each
stage are outlined below and in Figure 1 . The study proto-
col is published and the COS was prospectively registered
on the COMET database [12] . 
The scope was restricted to interventions that target the
decisions of adults deemed to have adequate mental capac-
ity and who are deciding, prospectively, about their own
participation in a randomized trial evaluating the effective-
ness of healthcare interventions. The ELICIT COS is fo-
cused on outcomes relevant to potential trial participants. 
Stage 1 - Generation of outcome list 
To generate the initial long list of outcomes, we first
conducted a systematic review of studies that had reported
or proposed outcome measures associated with decisions
to participate in trials. Detailed search strategies and a
PRISMA diagram are provided in supplementary informa-
tion files S1 and S2. The screening of titles, abstracts,
and potentially eligible studies was done by KG, with HG
reviewing a random 25%. Data extraction was conducted
by KG and HG independently for all included studies to
extract all relevant outcomes reported (or proposed), au-
thors rationale, definition, and operationalization of mea-
surement. Data on general characteristics of the included
studies (e.g., study type, setting, sample size, and where
appropriate, intervention being tested) were also extracted.
In addition, validated tools measuring informed consent
for clinical trials were reviewed and the specific domains
extracted. The review of tools is published elsewhere [13] .
The review was supplemented with interviews with na-
tional and international key stakeholders (i.e., potential trial
participants (e.g., patients or others who could provide
a lay perspective), trialists, research nurses, social scien-tists, clinicians, bioethicists, and research ethics commit-
tee members) to identify any additional outcomes of im-
portance. Participants were recruited from several sources,
namely: patients through the Scottish Health Research
Register (SHARE); Research Nurses through the Scottish
Research Nurse and Coordinators Network; Social Sci-
entists through the Society of Social Medicine; Research
Ethics Committee Members through the Health Research
Authority; and Ethicists through the Feminist Approaches
to Bioethics network. In addition, invites were sent through
known professional networks to key experts in the field,
targeting each of the groups mentioned above and target-
ing experienced clinical trialists. All participants gave writ-
ten consent to participate in a telephone interview. Inter-
views were supported by a topic guide to ensure coverage
of key issues. Interviewees described their experiences of
what a “good” consent process for clinical trials might
look like (See S3 file). All interviews were conducted by
KG, audio-recorded, and transcribed verbatim. A thematic
content analysis of the transcripts was conducted: follow-
ing familiarization with the transcripts, a priori and emer-
gent themes were identified, discussed and agreed by the
research team [14] . One author (K.G.) reviewed the tran-
scripts and documented major themes with 10% reviewed
independently (V.E.). A thematic framework was generated
and agreed through discussion by the team. The framework
detailed codes for labelling textual data related to the ma-
jor themes and subthemes. KG applied it systematically
to all transcripts using text management software (NVivo
V.10). 
Outcomes were extracted verbatim from the information
sources (systematic review and interviews), then grouped
into broad outcome domains determined through discus-
sion with the project team (supplementary information –S4
file). 
Stage 2 - International Delphi survey 
An international Delphi survey was used to seek agree-
ment on the relative importance of outcomes identified
from Stage 1. 
Each outcome generated from the systematic review and
interviews was listed together with a plain language defi-
nition on the online DelphiManager platform [15] – sup-
plementary information S5 Table. Individuals from the key
stakeholder groups listed previously were invited using na-
tional and international organizations (supplementary in-
formation – S6 file). We did not preclude participants who
had been involved in the interviews, but did not invite in-
terview participants directly to participate in the Delphi
survey. Whilst there is no standard sample size for the
“expert” panel in Delphi surveys, a minimum of 10-18
participants per expert group has been suggested [16 , 17] . 
Two rounds of the Delphi survey (R1 and R2) were
completed. The ELICIT protocol envisaged three rounds
of voting, as R2 originally planned a randomized evalua-
tion of different approaches to stakeholder feedback. How-
ever recent evidence emerged to support feedback by each
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stakeholder group (i.e., patients = 5, researchers = 6, clin-
icians = 5, etc) so this approach was instead adopted [18] .
In R1, the outcomes were presented and participants asked
to score their importance. A 9-point Likert scale was used,with 1-3 being not important and 7-9 being essential. This
scale has been recommended for consensus processes that
require a final validation (3-point scales may be preferred
for determining final consensus) [19] . R1 participants were
























































































also invited to submit any additional outcomes, which were
reviewed by the study team and considered for inclusion
in R2. No outcomes were removed between rounds. 
Only participants who completed R1 were invited to
participate in R2. During R2 each outcome was presented
to participants with their own R1 score and an anonymized
distribution of scores from each stakeholder group. Partic-
ipants were asked to score the outcome again, taking into
account the scores of others. 
2.2. Consensus definition 
Our original definition of consensus was based on pre-
vious COS studies and required that 70% or more of the
entire group had to agree as important (or not) and less
than 15% scoring in the opposite direction [20 , 21] . This
rule was applied successfully for determining "consensus
in,” however, the "consensus out” definition was subse-
quently amended (blinded to identity of outcomes) to 50%
or fewer participants scoring the outcome as important.
The reason for this change was that no outcomes met the
previously defined consensus "out” criterion but a large
number of outcomes were considered ”no consensus” (32
out of 43, 74%). This amendment has been used in sev-
eral recent COS studies [22] and allowed more explicit
demarcation of those outcomes which displayed the least
consensus. 
Stage 3 - Face-to-face consensus meeting 
In order to ratify the outcomes identified in the Delphi
survey, and provide an opportunity for discussion to clar-
ify any misunderstanding, a face-to-face consensus meet-
ing was held in Aberdeen, UK. Participants who had com-
pleted both rounds of the Delphi survey were invited. Ad-
ditional invitations were sent through social media to target
patients and researchers. Participants were sent a summary
of the study in advance and a consensus matrix detailing
the R2 summary scores for all outcomes– see supplemen-
tary information S7 file. Participants who took part in the
Delphi were also given a reminder of their R2 scores. 
As with Delphi surveys, there is no standard for sam-
ple sizes for consensus meetings. Reported numbers range
from two to 14, and some authors recommend a maxi-
mum of seven (for Nominal Group Technique) [23] . We
planned to recruit at least 5 participants from each stake-
holder group. These groups were reduced to ‘potential trial
participants’ and ‘researchers’ for the purposes of the con-
sensus meeting. 
The consensus meeting was chaired by a trials method-
ologist from the study team (MC) with expertise on COS
development methodology and consensus facilitation. Out-
comes that had reached consensus "in” across the whole
group from R2 were presented first, followed by outcomes
that reached consensus "out” across the whole group from
R2. Participants were asked to confirm they agreed (or not)
with the inclusion or exclusion of these outcomes in the
COS. Outcomes scored as ‘no consensus’ were split intotwo groups: 1. more than 50% of both groups scored the
outcome as 7-9 would be discussed and voted on again;
and 2. those with 50% or less of one group scoring 7-9
would not be voted on again. See supplementary informa-
tion file S8 Table for a summary of these re-scoring rules.
These "rules” for progression of outcomes for discussion
were agreed by the meeting participants before presenta-
tion and discussion of the outcomes. 
Views for and against inclusion of the outcomes for
which there was “no consensus” after R2 were sought by
the meeting chair. Discussion was supplemented with the
following questions: Is this outcome a surrogate for some-
thing already in the COS?; Does the group think it is re-
ally important to add?; Should it replace an outcome that
is already in (i.e., is there an outcome in the COS that
is a surrogate for this)? . Following discussion, partici-
pants were invited to vote on each outcome anonymously
on the PollEverywhere [https://www.polleverywhere.com/]
website through WiFi enabled devices. Following voting,
the whole group results were presented to participants. The
consensus definition used in the Delphi survey (see above)
was applied to determine consensus “in” or “out.”
2.3. Research ethics 
The study was approved by the London-Chelsea Re-
search Ethics Committee (REC reference 15/LO/0375). All
participants gave informed consent before taking part. 
2.4. Patient and public involvement 
Patients and the public were involved in developing
the Delphi survey, specifically through guidance on lay-
out, comprehensibility of items and scoring, and overall
objective. 
3. Results 
3.1. Generation of outcome list 
The systematic review identified 7767 titles and ab-
stracts for screening. Of those, 205 full text articles were
assessed for eligibility and 149 studies included in the fi-
nal analysis. These 149 studies included three broad study
types (studies using quantitative methods = 108, stud-
ies using qualitative methods = 28, and bioethics litera-
ture = 13 (see S2 file)). They yielded 1006 individually
characterized outcomes which were reduced to 33 distinct
outcome concepts (e.g., recruitment, understanding, deci-
sion conflict, coercion). 
A total of 25 interviews were conducted across the
stakeholder groups. Table 1 details full sample character-
istics. A total of 39 outcomes were identified in the inter-
views, of which 22 were "new” outcomes. 
The 33 outcomes from the literature review and the
22 additional outcomes from the interviews were com-
bined and reviewed by the study team. Fifteen outcomes
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Table 1. Interview sample demographics 
Patients (n = 4) Researchers (n = 21) 
Sub-group(s) Previous trial participants = 4 Researcher interested in trial design and conduct = 9 
Trial authorizer = 2 
Trial designer = 4 
Trial recruiter = 6 
Gender 75% female 38% female 
Experience of working on trials (yr) n/a Less than 1 = 1 
1-5 = 4 
6-10 = 4 
More than 10 = 12 
Country UK Australia = 1 
Canada = 1 
Ireland = 1 
Norway = 2 
UK = 12 































































were excluded - some overlapped (e.g., comprehension was
subsumed into understanding) and others related to health
systems or healthcare professionals rather than potential
trial participants. The remaining 40 outcomes were mapped
across four broad domains: 1. What decisions people make
and/or the quality of those decisions (n = 8); 2. Experi-
ences of decision making (n = 15); 3. How people make
decisions (n = 14); 4. Potential participants’ abilities rele-
vant to decision making that influence the decision (n = 3).
These were taken forward to the Delphi. 
3.2. International Delphi survey 
Round one of the Delphi survey was completed by 106
participants, and R2 by 79 (75% of those in R1) from 9
countries. The R2 sample comprised potential trial partic-
ipants (n = 6); previous trial participants (n = 11); re-
searchers interested in trial design and conduct (n = 22);
trial authorizers (n = 4); trial designers (n = 27); and trial
recruiters (n = 9) ( Table 2 ). 
At the end of R1, seven outcomes met the predefined
criteria for consensus at whole group level. Twenty-one
“new” outcomes were suggested for consideration and the
study team took 3 of these forwards for scoring in R2: cost
of intervention (development and implementation); the in-
dividual had the support they needed from others to reach
their decision; and salience of informed consent questions
to individual). The other suggested outcomes were ex-
cluded due to being out of scope (i.e., not relevant for
informed consent for adults with capacity to consent for
themselves in non-emergency settings) or duplicates. 
Following completion of R2, 11 outcomes achieved
consensus for inclusion in the COS at whole group level
and 12 for exclusion. Twenty outcomes were classified
"no consensus.” All were taken forward to the consensus
meeting. 3.3. Face-to-face consensus meeting 
The consensus meeting was attended by 18 participants
(6 patients and 12 researchers) from across the UK (see
Table 3 ). The group were first presented with the consen-
sus in (n-11) and the consensus out outcomes (n-12) and
asked if there were any they thought should be discussed.
The group decided that two outcomes ruled “out” at Del-
phi R2 should included in the voting and rescored. For the
no consensus outcomes, the rules for re-scoring (i.e., more
than 50% of both groups scored 7-9) were agreed and this
resulted in 13 outcomes being taken forward for scoring.
The group also asked for one further outcome from the no
consensus group (n = 7) to be rescored, so 14 outcomes
from the no consensus group were taken forward. Sixteen
outcomes in total (14 "no consensus” and 2 "consensus
out”) were taken forward for full discussion and re-voting.
Supplementary Information Table S9 shows meeting par-
ticipants’ scores on the 16 outcomes that were re-voted. 
There were discussions on nearly all of the outcomes
presented, and focused discussions on the 16 taken forward
for re-scoring. We focus here on three outcomes that re-
ceived considerable attention: trust, understanding and re-
cruitment. Trust and understanding had scored consensus
“out” in the Delphi but been elevated for discussion and
re-scoring in the meeting. The decision to re-score trust
was based on it being the only consensus “out” outcome
with a marked difference in scoring between stakeholder
groups (94% of patients and 11% of researchers scored
it 7-9). Meeting attendees argued that trust could be cov-
ered through other outcomes already included e.g., feeling
comfortable with the decisions, and on re-scoring trust was
agreed as consensus “out.” Discussion about understanding
centered around how it was, or was not, linked to knowl-
edge and communication, both outcomes that were already
considered consensus “in.” Some patient participants felt
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Table 2. Delphi sample demographics 
Patients (n = 17) Researchers (n = 62) 
Sub-group Potential trial participants = 6 Researcher interested in trial design and conduct = 22 
Previous trial participants = 11 Trial authorizer = 4 
Trial designer = 27 
Trial recruiter = 9 
Gender 53% female 59% female 
Experience of working on trials (yr) Never involved = 5 Never involved = 0 
Less than 1 = 1 Less than 1 = 0 
1-3 = 1 1-3 = 6 
3-5 = 2 3-5 = 7 
5-10 = 5 5-10 = 16 
More than 10 = 3 More than 10 = 33 
Country Canada = 1 Australia = 1 
Ireland = 1 Brazil = 1 
UK = 15 Canada = 1 
India = 1 
Ireland = 2 
Malaysia = 1 
Switzerland = 1 
UK = 51 
USA = 3 
Table 3. Consensus meeting demographics 
Group Patients = 6 
Researchers = 12 
Gender 55% female 
Experience of working on trials (yr) Never involved = 1 
1-3 = 2 
3-5 = 4 
5-10 = 5 









































that having only knowledge as an outcome was not appro-
priate as the symptoms of some diseases or side effects of
relevant treatments can impact on an individual’s ability to
recall information (which was equated with knowledge).
They thought it important to include an additional mea-
sure of "informedness.” Others considered that the three
outcomes of knowledge, understanding and communica-
tion exist in a causal chain and by excluding one of these
outcomes it would not allow investigations of this model.
When the group re-scored after discussion, understanding
was scored consensus "in.”
Recruitment was the only consensus "out” or "no con-
sensus” outcome from the Delphi (n = 32) that more than
70% of researchers (74%) and less than 70% of patients
(47%) had scored important (i.e., 7-9). Discussion of re-
cruitment as an outcome was extensive and opinion di-
vided. Some participants (both researchers and patients)
felt strongly that recruitment should not be regarded as amarker of, or proxy for, the "quality” of informed consent
processes. There was concern that trial teams might treat a
negative impact on recruitment as indicative of “harm” and
argue that even if all other aspects of the informed con-
sent process were deemed "good,” it should rule out use
of the intervention. However, other participants (again both
researchers and patients) considered it important to assess
any detriment to recruitment, and argued in practical terms
that, for example, if an intervention halved the recruitment
rate but had a positive impact on decision making, this
information could be used for recruitment planning. At re-
scoring, it was considered “no consensus.”
3.4. The core outcome set 
The final COS includes 12 outcomes grouped across 3
domains ( Table 4 ). These were: therapeutic misconception;
comfort with decision; authenticity of decision; communi-
cation about the trial; empowerment; sense of altruism;
equipoise; knowledge; salience of questions; understand-
ing, how helpful the process was for decision making; and
attrition from the trial. 
4. Discussion 
This study developed the first internationally agreed
COS for evaluating interventions to improve decisions
about participating in an RCT. It accounts for the views of
all key stakeholders. 
During the Delphi, patients generally rated more items
as critically important for inclusion in a COS than re-
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Table 4. Outcomes included in the ELICIT core outcome set 
Outcome (n = 12) Domain 
Whether a potential participant is comfortable (feels happy and relaxed) with the decision. a Experiences of decision-making in this context. 
How helpful a potential participant finds the consent process to make a decision. 
The authenticity of a potential participant’s decision, i.e., how genuine their decision was. a 
The communication (both written and verbal) about the trial. a 
Feelings of empowerment (the process of becoming stronger and more confident, especially 
in controlling one’s life and claiming one’s right) from the perspective of a potential 
participant. a 
Salience of informed consent questions to individual. b 
A potential participant’s sense of altruism (selfless concern for the well-being of others). How people make decisions. 
Uncertainty about the comparative therapeutic merits of each treatment being tested in a 
trial (equipoise). 
A potential participant’s knowledge, i.e., the recall of facts, information or skills. 
A potential participant’s understanding, i.e., the ability to comprehend something without 
necessarily knowing how it relates to or affects other things. 
A potential participant’s understands that the treatment they receive will not be 
individualized and the overall purpose of the research is to advance scientific knowledge 
rather than benefiting them personally (therapeutic misconception). 
What decisions people make and/or the quality 
of those decisions. 
The proportion of trial participants who do not complete the trial (attrition). 
a Outcome identified during stakeholder interviews. 





























































searchers. In R2, based on patients’ scores alone, 30 out-
comes would have been considered in compared to 10 for
researchers. One comment from the meeting was that it
became easier to be more discriminating when a proposed
core set (based on the R2 result) was presented as a stan-
dard to consider against. When considering each outcome
in isolation, assessment of importance may have been cog-
nitively harder. In addition, the face-to-face meeting pro-
vided opportunities for clarification of the overall purpose
of the ELICIT COS and further discussion of what out-
comes might mean. 
It is important to consider where the outcomes that fea-
ture in the ELICIT COS entered the COS development
process. Four (33%) of the 12 were identified only through
interviews with stakeholders. In other words, they had not
been previously measured or reported in studies investi-
gating decision processes for RCTs. In addition, one out-
come (the salience of informed consent questions) was
suggested for the first time in the Delphi (the remaining
7 were identified from the systematic review phase). This
provides reassurance that the ELICIT process enabled the
contributions of key stakeholders to be heard and repre-
sented in the final output. It is also important to high-
light that the decision of the Delphi survey was maintained
through the consensus meeting with all 11 Delphi “in” out-
comes being retained in the final core set and the addition
of one further outcome from the “no consensus” Delphi
group. 
An important finding is the exclusion of trial recruit-
ment rate as a core outcome for these interventions.
Within the systematic review, trial recruitment was the
third most frequently reported outcome (after understand-ing and knowledge), cited in 54 (44%) of the 122 studies.
It was the only outcome about which consensus meeting
participants’ opinions were polarized (and across both pa-
tients and researchers). In contrast to recruitment, attrition
was included in the ELICIT COS with consensus meeting
participants commenting that it would provide information
about longer term impact of the quality of the decision.
However, this needs to be considered with caution as at-
trition may be strongly influenced by various factors other
than interventions to support decision-making about trial
participation. 
Some interpretive caution will be needed for other COS
elements too, as they vary in proximity to (different aspects
of) interventions intended to improve informed consent
processes and may be variously influenced or moderated,
including by each other. As was evident in the consensus
meeting, outcome descriptors can be variously understood,
and ideas about causal and other relationships between dif-
ferent COS elements can vary depending on how they are
defined and operationalized. 
The ELICIT study identified "what”outcomes needs to
be measured, but not "how.” Measurement tools exist for
some of the outcomes listed in the COS (e.g., therapeutic
misconception [24] , understanding [25] have been assessed
in RCT settings and other outcomes in non-RCT settings
[26 , 27] ). It will be important to determine how fit these
are for purpose, whether new tools are needed, and (more
fundamentally) how measurable some outcomes are, espe-
cially across different trial contexts. Measurement issues
will be key when moving this work forward. Specific at-
tention to ensuring construct validity through the use of,
for example, cognitive interviewing, will be key to robust
















































































measurement. Given the COS contains 12 outcomes, con-
sidering the data collection burden for each of these out-
comes is also important for future work e.g., can some of
these outcomes be combined, could they be measured with
tools containing 1 item, etc. 
Further methodological work linked to ELICIT is ongo-
ing. This includes a COS for evaluation of interventions to
improve the informed consent process for elective surgical
procedures [27] and a COS for interventions to improve in-
formed consent to trials for adults who lack capacity [28] .
The growth of COS work in methodological areas high-
lights the problem of outcome measurement and reporting
that extends beyond clinical studies. It reinforces the crit-
ical importance of these COS to contribute to efforts to
reduce research waste and improve patient care. 
4.1. Strengths and limitations 
A strength of the process was the inclusion of patient
partners at each stage of development from generation of
the long list through to ratification of the final COS in the
consensus meeting. Their involvement ensured a COS that
considers what matters most to potential trial participants
about the informed consent process. 
Although outcomes of international relevance were well
represented in the systematic review and 43% of interview
participants were non-UK, only 18% of Delphi participants
were from outside the UK, and only 3% of those from low-
or middle-income countries. Nearly all of the patients in-
volved in the ELICIT Study were UK based and were flu-
ent English speakers. This raises considerations about the
relevance of the COS in countries dissimilar to the UK. For
example, healthcare funding arrangements and cultural dif-
ferences in relational dynamics could affect patients’ deci-
sions about trial participation and raise important questions
for further research. An additional limitation is the po-
tential attrition bias associated with the two round Delphi
survey. Whilst attempts were made to reengage with non-
responders, 25% did not provide data for the final analysis.
It cannot be ruled out that participants who did not com-
plete Round 2 had views which differed. 
5. Conclusions 
The ELICIT COS provides an internationally agreed
minimum set of outcomes that should be measured in
all future studies evaluating interventions to improve how
adults with capacity prospectively, make decisions about
participating in an RCT. It represents outcomes that are of
core importance to multiple stakeholders and, if adopted,
will improve the relevance of future trials in this field. Up-
take of the ELICIT COS will also impact directly on the
potential for cross-learning and synthesis of results from
across different trial settings, thus maximizing efficiency
and reducing research waste. Acknowledgments 
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